---
title: "Creative Medical net loss widens 22.5% to $1.51 million in Q2 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295279892.md"
description: "Creative Medical Technology Holdings reported a Q2 2026 net loss of $1.51 million, widening from $1.23 million in the prior year. SG&A expenses rose 48% to $1.08 million due to increased marketing, while R&D costs fell 8% to $459,200 as the CELZ-201 ADAPT trial entered follow-up. The company generated no revenue but saw other income rise to $50,913. Cash and US Treasuries stood at $8.71 million."
datetime: "2026-08-07T21:23:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295279892.md)
  - [en](https://longbridge.com/en/news/295279892.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295279892.md)
---

# Creative Medical net loss widens 22.5% to $1.51 million in Q2 2026

-   Creative Medical Technology Holdings posted a Q2 net loss of USD 1.51 million, widening from USD 1.23 million a year earlier. \* Selling, general and administrative expense climbed 48% to USD 1.08 million, driven by higher marketing spend tied to a company-level campaign. \* Research and development expense fell 8% to USD 459,200 as the CELZ-201 ADAPT trial moved into follow-up, partly offset by broader platform investment. \* Other income rose to USD 50,913 from USD 30,217 on higher short-term investment balances, while no revenue was generated. \* FDA cleared an ADAPT trial expansion in June to add patients with ongoing opioid use; cash and US Treasuries totaled USD 8.71 million at June 30. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004779), on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CELZ.US](https://longbridge.com/en/quote/CELZ.US.md)

## Related News & Research

- [Metalfrio Solutions signs off on Q2 2026 financial statements](https://longbridge.com/en/news/296394445.md)
- [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md)
- [Legacy Housing sets 2026 annual shareholder meeting in virtual format](https://longbridge.com/en/news/295958931.md)
- [Caterpillar declares Q3 2026 distribution of R$ 0.35 per unit, payable Aug. 26](https://longbridge.com/en/news/296394630.md)
- [LSEB Creative delays quarterly report filing after review process runs late](https://longbridge.com/en/news/296101192.md)